.png)
.png)
Japanese Cell Therapy Programs
Japan Cell Clinic partners exclusively with premier Japanese immunotherapy specialist hospitals and will guide you through every step, ensuring you experience world-class immune cell therapy.
Adipose-Derived Stem Cells
- Extract a small fat sample (equivalent to 4 grains of rice) → Culture in patient's autologous serum → Re-infuse.
- Fresh cultivation without cryopreservation maximizes cell viability (100–200 million cells administered per session).
- A single extraction allows for multiple treatment sessions, minimizing physical burden on the patient.
Umbilical Cord Blood Stem Cells
- Uses healthy donor stem cells (allogeneic stem cells) derived from umbilical cord blood.
- Safe with minimal risk of immune rejection and free from viral contamination.
- Exceptional regenerative and differentiation capabilities, effective for intractable and neurological conditions.
.png)
NK Immune Cell Therapy
- Extract NK cells from patient's blood → Activate and culture with high-concentration IL-2 → Re-infuse.
- Average 65% activation rate (at least 3 billion cells).
- Directly attacks cancer cells and helps prevent recurrence; can be combined with Opdivo and Yervoy.
iNKT Cell Cancer Immunotherapy
- Cultured iNKT cells are infused to broadly target and attack cancer cells, regardless of the presence of antigens.
- Activates NK and cytotoxic T cells via IFN-γ secretion for sustained long-term efficacy.
- iNKT cell therapy is available exclusively at 'Maki Clinic,' authorized by Japan's Ministry of Health, Labour and Welfare.
.png)
Exosome Therapy
- Promotes tissue recovery and regeneration through intercellular signaling.
- Provides immunomodulatory effects with higher safety and cost-efficiency compared to stem cell therapies.
- Exosome therapy is a highly effective, cost-efficient next-generation regenerative treatment.
NK cell therapy enhanced concurrent therapy
Nivolumab
Restoring anticancer responses by blocking the PD-1 pathway of T cells
Opdivo, developed based on research on the PD-1 protein discovered by Dr. Tasuku Honjo of Japan (Nobel Prize winner in 2018), is a treatment that blocks the PD-1 pathway of immune cells, preventing cancer cells from evading immune cell attacks and restoring anticancer responses.
Yervoy (Ipilimumab)
Amplify T cell activation by inhibiting CTLA-4
This antibody therapy, discovered by Dr. James P. Allison in the United States, boosts T-cell activation by inhibiting the CTLA-4 protein. Blocking CTLA-4 helps to strengthen the immune response against cancer.
Opdivo (Nivolumab) and Yervoy (Ipilimumab) are immune-boosting drugs developed from research achievements recognized with the **2018 Nobel Prize in Physiology or Medicine (announced by the Nobel Prize Committee)**.[1][2]
These two treatments, when combined with NK, iNKT, and activated T-cell therapy, help enhance the immune response and improve treatment efficacy. Furthermore, immune-enhancing treatment combining NK cells with Opdivo/Yervoy is only available in Nagoya, where physicians can directly manage the treatment, due to the risk of "immune overload."
References and official sources
[1] Nobel Prize in Physiology or Medicine 2018 – Press Release, Nobel Prize official site
https://www.nobelprize.org/prizes/medicine/2018/press-release/
[2] Nobel Prize 2018 – Advanced Information (PD-1 & CTLA-4 research)
https://www.nobelprize.org/prizes/medicine/2018/advanced-information/
[3] GenScript – Nobel Prize for Cancer Immunotherapy (checkpoint inhibitors in practice)
https://www.genscript.com/gene-news/cancer-immunotherapy-nobel-prize.html
Process
Adipose-Derived Stem Cell Therapy
🧬 Step 1: Fat Tissue Collection (Approximately 4 grains of rice)
-
A minimal amount of adipose tissue (equivalent to approximately 4 grains of rice) is collected from the abdomen under local anesthesia.
-
The procedure is minimally invasive with minimal pain or scarring, allowing patients to resume daily activities immediately.
-
A single extraction provides sufficient cells for 3 to 5 treatment sessions without requiring repeated collections.
🔬 Step 2: Cell Culture (GMP Standard Facility, Approximately 3–4 Weeks)
-
Cultured in a fresh, non-frozen state to maintain maximum cell viability and biological activity.
-
Strictly cultured using the patient’s own autologous serum without animal serum or antibiotics, ensuring superior safety.
-
Expanded and verified to reach 100 to 200 million active stem cells per dose in a Japanese GMP-certified facility.
💉 Step 3: Administration (Stem Cell Infusion)
-
The expanded autologous stem cells (100–200 million cells) are administered via intravenous (IV) drip.
-
Stem cells circulate through the bloodstream, naturally migrating to damaged blood vessels, organs, and tissues to promote repair and regeneration.
-
Promotes vascular recovery, organ function improvement, chronic inflammation reduction, and systemic anti-aging.
📈 Step 4: Monitoring (Post-Treatment Care)
-
Physical condition, vitality, and functional recovery are monitored following administration.
-
Seamless aftercare and personalized health consultations are available through collaboration with both Tokyo and Nagoya partner clinics.
Umbilical Cord Blood Stem Cell Therapy
📋 Step 1: Patient Evaluation & Cell Matching (No Harvesting Required)
-
Optimal cord blood stem cells are matched and selected based on the patient's condition, age, and weight.
-
No blood or tissue collection is required from the patient, completely eliminating physical burden and discomfort.
-
Exclusively sourced from certified cord blood banks following rigorous screening for viruses and infectious pathogens.
🔬 Step 2: Cell Thawing & Activation (Sterile Laboratory Preparation)
-
High-purity cryopreserved cord blood stem cells are precision-thawed and activated in a sterile facility immediately prior to treatment.
-
Sourced from pristine newborn cord blood without environmental exposure, presenting minimal risk of immune rejection.
-
Rich in hematopoietic and mesenchymal stem cells with superior self-renewal and multi-lineage differentiation capabilities.
💉 Step 3: Administration (Intravenous Infusion)
-
The activated cord blood stem cells are administered safely and comfortably via standard intravenous (IV) drip.
-
With no patient cell harvesting or lengthy 3–4 week culture wait time, treatment can be scheduled promptly for overseas patients.
-
Highly effective for neurological condition support, intractable disease recovery, and systemic immune balance restoration.
Step 4: Monitoring (Post-Treatment Care)
-
The patient's recovery progress and physiological responses are closely observed following infusion.
-
Comprehensive aftercare and VIP medical concierge support are coordinated across our Tokyo and Nagoya clinics.
NK Immune Cell Therapy
🩸 Step 1: Blood collection (approximately 30 mL)
-
Approximately 30 mL of peripheral blood is collected from the patient.
-
It is similar to a regular blood test, and there is no significant pain or burden.
-
NK cell immune cells are isolated from the collected blood.
🔬 Step 2: Cell Culture
(GMP standard facility, approximately 2 weeks)
Isolated immune cells are activated using high concentrations of IL-2, antibodies, and special techniques.
Strictly managed in a Japanese GMP (Good Manufacturing Practice) certified facility.
During this process, the proportion of NK cells increases to an average of 65% of total lymphocytes (range: 45–85%), although it is typically around 20%.
After two weeks of proliferation and quality verification, patient-specific cells are prepared.
💉 Step 3: Administration (Cell Injection)
-
Activated and expanded immune cells are infused back into the patient's body via intravenous injection.
-
Can be used in conjunction with standard chemotherapy. Immune checkpoint inhibitors (such as Opdivo and Yervoy) have been reported to exhibit synergistic effects when combined with cell therapy, and the attending physician determines combination suitability based on the patient's condition.
📈 Step 4: Monitoring (Post-Treatment Progress Management)
-
After administration, immune cell activity and the patient's condition are observed for a certain period.
-
Can be combined with supportive therapies (e.g., nutritional injections, immune enhancement therapy) if necessary.
-
For the convenience of patients, aftercare is available through collaboration with both Tokyo and Nagoya clinics.
01. Official approval from the Japanese Ministry of Health, Labor and Welfare
02. Can be used in conjunction with standard chemotherapy, minimizing side effects.
03. Based on internationally verified clinical data
Safety & Evidence
Frequently Asked Questions
Q: Are there any side effects?
Temporary reactions such as high fever may occur, but they will be safely managed at our partner clinic.
Q: Can I receive cell therapy while undergoing chemotherapy?
Yes, concurrent treatment is possible. We will guide you on the optimal method based on your condition.
Q: Can I receive treatment in Nagoya as well?
Yes, we collaborate not only with Tokyo but also with our partner clinic in Nagoya. The Nagoya clinic is equipped with X-ray and ultrasound diagnostic equipment, allowing us to demonstrate the treatment effects through video.
Japan Cell Clinic
For your safe and comfortable Japanese cell therapy,
We operate a counseling channel.
or
JCC consultation number:
+81-70-8983-8971
